These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34359961)

  • 1. Consequences of SUR2[A478V] Mutation in Skeletal Muscle of Murine Model of Cantu Syndrome.
    Scala R; Maqoud F; Zizzo N; Passantino G; Mele A; Camerino GM; McClenaghan C; Harter TM; Nichols CG; Tricarico D
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular consequences of KATP overactivity in Cantu syndrome.
    Huang Y; McClenaghan C; Harter TM; Hinman K; Halabi CM; Matkovich SJ; Zhang H; Brown GS; Mecham RP; England SK; Kovacs A; Remedi MS; Nichols CG
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiological Consequences of KATP Channel Overactivity and Pharmacological Response to Glibenclamide in Skeletal Muscle of a Murine Model of Cantù Syndrome.
    Scala R; Maqoud F; Zizzo N; Mele A; Camerino GM; Zito FA; Ranieri G; McClenaghan C; Harter TM; Nichols CG; Tricarico D
    Front Pharmacol; 2020; 11():604885. PubMed ID: 33329006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent K
    Scala R; Maqoud F; McClenaghan C; Harter TM; Perrone MG; Scilimati A; Nichols CG; Tricarico D
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential mechanisms of Cantú syndrome-associated gain of function mutations in the ABCC9 (SUR2) subunit of the KATP channel.
    Cooper PE; Sala-Rabanal M; Lee SJ; Nichols CG
    J Gen Physiol; 2015 Dec; 146(6):527-40. PubMed ID: 26621776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cantu syndrome-associated SUR2 (ABCC9) mutations in distinct structural domains result in K
    McClenaghan C; Hanson A; Sala-Rabanal M; Roessler HI; Josifova D; Grange DK; van Haaften G; Nichols CG
    J Biol Chem; 2018 Feb; 293(6):2041-2052. PubMed ID: 29275331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex consequences of Cantu syndrome SUR2 variant R1154Q in genetically modified mice.
    Zhang H; Hanson A; de Almeida TS; Emfinger C; McClenaghan C; Harter T; Yan Z; Cooper PE; Brown GS; Arakel EC; Mecham RP; Kovacs A; Halabi CM; Schwappach B; Remedi MS; Nichols CG
    JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33529173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiologic consequences of KATP gain of function in the heart: Conduction abnormalities in Cantu syndrome.
    Levin MD; Zhang H; Uchida K; Grange DK; Singh GK; Nichols CG
    Heart Rhythm; 2015 Nov; 12(11):2316-24. PubMed ID: 26142302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity.
    McClenaghan C; Huang Y; Yan Z; Harter TM; Halabi CM; Chalk R; Kovacs A; van Haaften G; Remedi MS; Nichols CG
    J Clin Invest; 2020 Mar; 130(3):1116-1121. PubMed ID: 31821173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kir6.1-dependent K
    Davis MJ; Kim HJ; Zawieja SD; Castorena-Gonzalez JA; Gui P; Li M; Saunders BT; Zinselmeyer BH; Randolph GJ; Remedi MS; Nichols CG
    J Physiol; 2020 Aug; 598(15):3107-3127. PubMed ID: 32372450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conserved functional consequences of disease-associated mutations in the slide helix of Kir6.1 and Kir6.2 subunits of the ATP-sensitive potassium channel.
    Cooper PE; McClenaghan C; Chen X; Stary-Weinzinger A; Nichols CG
    J Biol Chem; 2017 Oct; 292(42):17387-17398. PubMed ID: 28842488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cantú syndrome resulting from activating mutation in the KCNJ8 gene.
    Cooper PE; Reutter H; Woelfle J; Engels H; Grange DK; van Haaften G; van Bon BW; Hoischen A; Nichols CG
    Hum Mutat; 2014 Jul; 35(7):809-13. PubMed ID: 24700710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCC9-related Intellectual disability Myopathy Syndrome is a K
    Smeland MF; McClenaghan C; Roessler HI; Savelberg S; Hansen GÅM; Hjellnes H; Arntzen KA; Müller KI; Dybesland AR; Harter T; Sala-Rabanal M; Emfinger CH; Huang Y; Singareddy SS; Gunn J; Wozniak DF; Kovacs A; Massink M; Tessadori F; Kamel SM; Bakkers J; Remedi MS; Van Ghelue M; Nichols CG; van Haaften G
    Nat Commun; 2019 Oct; 10(1):4457. PubMed ID: 31575858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K(ATP) channel gain-of-function leads to increased myocardial L-type Ca(2+) current and contractility in Cantu syndrome.
    Levin MD; Singh GK; Zhang HX; Uchida K; Kozel BA; Stein PK; Kovacs A; Westenbroek RE; Catterall WA; Grange DK; Nichols CG
    Proc Natl Acad Sci U S A; 2016 Jun; 113(24):6773-8. PubMed ID: 27247394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphatic contractile dysfunction in mouse models of Cantú Syndrome with K
    Davis MJ; Castorena-Gonzalez JA; Kim HJ; Li M; Remedi M; Nichols CG
    Function (Oxf); 2023; 4(3):zqad017. PubMed ID: 37214333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A new type of ATP-sensitive potassium channelopathy : Cantú syndrome].
    Hiraki Y; Takanari H
    No To Hattatsu; 2016 Sep; 48(5):325-31. PubMed ID: 30010274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kir6.1 and SUR2B in Cantú syndrome.
    McClenaghan C; Nichols CG
    Am J Physiol Cell Physiol; 2022 Sep; 323(3):C920-C935. PubMed ID: 35876283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Characterization of the Functional and Pharmacological Consequences of Cantú Syndrome K
    Gao J; McClenaghan C; Matreyek KA; Grange DK; Nichols CG
    J Pharmacol Exp Ther; 2023 Sep; 386(3):298-309. PubMed ID: 37527933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glibenclamide treatment in a Cantú syndrome patient with a pathogenic ABCC9 gain-of-function variant: Initial experience.
    Ma A; Gurnasinghani S; Kirk EP; McClenaghan C; Singh GK; Grange DK; Pandit C; Zhu Y; Roscioli T; Elakis G; Buckley M; Mehta B; Roberts P; Mervis J; Biggin A; Nichols CG
    Am J Med Genet A; 2019 Aug; 179(8):1585-1590. PubMed ID: 31175705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphedema as first clinical presentation of Cantu Syndrome: reversed phenotyping after identification of gain-of-function variant in ABCC9.
    Gao J; McClenaghan C; Christiaans I; Alders M; van Duinen K; van Haelst MM; van Haaften G; Nichols CG
    Eur J Hum Genet; 2023 Feb; 31(2):188-194. PubMed ID: 36336713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.